NCT06212349 Therapeutic-educational Physiotherapy on Pain, Physical-functionality and Quality of Life in Women With Endometriosis.
| NCT ID | NCT06212349 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Valencia |
| Condition | Endometriosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 62 participants |
| Start Date | 2024-09-09 |
| Primary Completion | 2027-09-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 62 participants in total. It began in 2024-09-09 with a primary completion date of 2027-09-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized clinical trial that will be carried out in women with endometriosis divided into two groups: the experimental group (EG) that will receive therapeutic-educational physiotherapy, which will combine therapeutic exercise with a pain education program, and the control group (CG) who will receive the pain education program. The participants will be evaluated at three moments: before starting the study (T1), after the 8-week treatment program (T2) and after another 8 weeks of follow-up in which they will be encouraged to continue with the treatment (T3). The initial assessment will include a medical and physiotherapy history, and at T1, T2 and T3 the following will be assessed: pain, abdominopelvic mobility, muscle status, functionality, sexual function, quality of life, stress and biomarkers of chronic inflammation.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of endometriosis made by imaging techniques (MRI or ultrasound) or by surgery. * A period of 3 months or more since the last surgery if they have undergone surgery. * Who are receiving hormone treatment and have their disease under control. * Persistent pelvic pain for at least 3 months. * With pain and hypertonus in the pelvic musculature, myofascial syndrome, vestibulodynia or pudendal neuropathy. * Consent to participate in the study * Capable of carrying out the follow-up of the study until the final visit. * Who have audiovisual resources and the internet at their disposal. Exclusion Criteria: * Women in the menopausal phase * Women undergoing fertility treatment or planning to undergo fertility treatment in the next 3 months. * Pregnant women. * Women undergoing physiotherapy treatment or who have undergone physiotherapy treatment in the last 3 months. * Having suffered a fracture in the last 3 months in the lower limb that limits their functional capacity. * Cognitive illness that prevents correct comprehension of the exercises. * Musculoskeletal pathology or neuropathy in acute phase. * Having suffered or suffering from a neoplastic disease. * Untreated endometriosis * Acquired genital abnormalities of the pelvis or pelvic floor. * Women in a situation of litigation or economic compensation, or pending the granting of a degree of disability. * Severe mental illness (schizophrenia, borderline personality disorder, etc.)
Contact & Investigator
laura Fuentes Aparicio, PhD
PRINCIPAL INVESTIGATOR
University of Valencia
Frequently Asked Questions
Who can join the NCT06212349 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Endometriosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06212349 currently recruiting?
Yes, NCT06212349 is actively recruiting participants. Contact the research team at ijuapa@gmail.com for enrollment information.
Where is the NCT06212349 trial being conducted?
This trial is being conducted at Valencia, Spain.
Who is sponsoring the NCT06212349 clinical trial?
NCT06212349 is sponsored by University of Valencia. The principal investigator is laura Fuentes Aparicio, PhD at University of Valencia. The trial plans to enroll 62 participants.